Close Menu

Bucindolol, a beta-blocker that never made it to the market because a patient study showed it did not reduce the risk of death due to high blood pressure and heart failure, may be making a comeback. According to the Wall Street Journal, researchers report that heart failure patients with a specific genetic mutation given the drug were 48 percent less likely to die of heart-related problems and 44 percent less likely to be hospitalized, as compared to those given placebo.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

Novavax has begun a phase III trial of its SARS-CoV-2 vaccine, according to the New York Times.

Vox reports that the Trump Administration may limit student visas for individuals from some countries to two years.

The governor of New York says the state will conduct its own review of any SARS-CoV-2 vaccine, NPR reports.

This week in Science: Neanderthal Y chromosomes replaced by Homo sapiens Y chromosomes, and more.